Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

283 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors.
Jiménez-Fonseca P, Carmona-Bayonas A, Martín-Pérez E, Crespo G, Serrano R, Llanos M, Villabona C, García-Carbonero R, Aller J, Capdevila J, Grande E; Spanish Neuroendocrine Tumor Group (GETNE). Jiménez-Fonseca P, et al. Among authors: crespo g. Cancer Metastasis Rev. 2015 Sep;34(3):381-400. doi: 10.1007/s10555-015-9573-1. Cancer Metastasis Rev. 2015. PMID: 26245646 Review.
Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis.
Capdevila J, Sevilla I, Alonso V, Antón Aparicio L, Jiménez Fonseca P, Grande E, Reina JJ, Manzano JL, Alonso Lájara JD, Barriuso J, Castellano D, Medina J, López C, Segura Á, Carrera S, Crespo G, Fuster J, Munarriz J, García Alfonso P. Capdevila J, et al. Among authors: crespo g. BMC Cancer. 2015 Jul 4;15:495. doi: 10.1186/s12885-015-1512-6. BMC Cancer. 2015. PMID: 26138480 Free PMC article.
Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study.
Carmona-Bayonas A, Jiménez-Fonseca P, Lamarca Á, Barriuso J, Castaño Á, Benavent M, Alonso V, Riesco-Martínez MDC, Alonso-Gordoa T, Custodio A, Sánchez Cánovas M, Hernando Cubero J, López C, Lacasta A, Fernández Montes A, Marazuela M, Crespo G, Escudero P, Diaz JÁ, Feliciangeli E, Gallego J, Llanos M, Segura Á, Vilardell F, Percovich JC, Grande E, Capdevila J, Valle JW, García-Carbonero R. Carmona-Bayonas A, et al. Among authors: crespo g. J Clin Oncol. 2019 Oct 1;37(28):2571-2580. doi: 10.1200/JCO.19.00980. Epub 2019 Aug 7. J Clin Oncol. 2019. PMID: 31390276 Free PMC article.
Usefulness of an immunohistochemical score in advanced pancreatic neuroendocrine tumors treated with CAPTEM or everolimus.
Viúdez A, Crespo G, Gómez Dorronsoro ML, Arozarena I, Marín-Méndez JJ, Custodio A, Benavent M, Goñi S, García-Paredes B, Hernando J, Durantez M, Alonso V, Riesco MDC, López C, Jiménez-Fonseca P, San Vicente BL, González-Borja I, Sevilla I, Hernández-Garcia I, Carmona-Bayonas A, Capdevila J, Pérez-Sanz J, García-Carbonero R, Pérez-Ricarte L, Llanos M, Vera R, De Jesús Acosta A. Viúdez A, et al. Among authors: crespo g. Pancreatology. 2021 Jan;21(1):215-223. doi: 10.1016/j.pan.2020.12.009. Epub 2020 Dec 19. Pancreatology. 2021. PMID: 33358592
External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study.
Jimenez-Fonseca P, Carmona-Bayonas A, Lamarca A, Barriuso J, Castaño A, Benavent M, Alonso V, Riesco MDC, Alonso-Gordoa T, Custodio A, Sanchez Canovas M, Hernando J, López C, La Casta A, Fernandez Montes A, Marazuela M, Crespo G, Diaz JA, Feliciangeli E, Gallego J, Llanos M, Segura A, Vilardell F, Percovich JC, Grande E, Capdevila J, Valle J, Garcia-Carbonero R. Jimenez-Fonseca P, et al. Among authors: crespo g. Neuroendocrinology. 2022;112(1):88-100. doi: 10.1159/000514808. Epub 2021 Jan 28. Neuroendocrinology. 2022. PMID: 33508849
Physician-perceived utility of the EORTC QLQ-GINET21 questionnaire in the treatment of patients with gastrointestinal neuroendocrine tumours: a multicentre, cross-sectional survey (QUALINETS).
Benavent M, Sastre J, Escobar IG, Segura A, Capdevila J, Carmona A, Sevilla I, Alonso T, Crespo G, García L, Canal N, de la Cruz G, Gallego J. Benavent M, et al. Among authors: crespo g. Health Qual Life Outcomes. 2021 Jan 30;19(1):38. doi: 10.1186/s12955-021-01688-x. Health Qual Life Outcomes. 2021. PMID: 33516211 Free PMC article.
Initial clinical and treatment patterns of advanced differentiated thyroid cancer: ERUDIT study.
Vallejo Casas JA, Sambo M, López López C, Durán-Poveda M, Rodríguez-Villanueva García J, Santos RJ, Llanos M, Navarro-González E, Aller J, Pubul V, Guadalix S, Crespo G, González C, Zafón C, Navarro M, Santamaría-Sandi J, Segura Á, Gajate P, Gómez-Balaguer M, Valdivia J, Puig-Domingo M, Galofré JC, Castelo B, Villanueva MJ, Argüelles I, Orcajo-Rincón L. Vallejo Casas JA, et al. Among authors: crespo g. Eur Thyroid J. 2022 Aug 11;11(5):e210111. doi: 10.1530/ETJ-21-0111. Print 2022 Oct 1. Eur Thyroid J. 2022. PMID: 35900793 Free PMC article.
Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin.
Capdevila J, Hernando J, Teule A, Lopez C, Garcia-Carbonero R, Benavent M, Custodio A, Garcia-Alvarez A, Cubillo A, Alonso V, Carmona-Bayonas A, Alonso-Gordoa T, Crespo G, Jimenez-Fonseca P, Blanco M, Viudez A, La Casta A, Sevilla I, Segura A, Llanos M, Landolfi S, Nuciforo P, Manzano JL. Capdevila J, et al. Among authors: crespo g. Nat Commun. 2023 May 23;14(1):2973. doi: 10.1038/s41467-023-38611-5. Nat Commun. 2023. PMID: 37221181 Free PMC article. Clinical Trial.
283 results